140 related articles for article (PubMed ID: 38778121)
1. Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage.
Li LG; Peng XC; Yang ZY; Han N; Gou CL; Shi J; Yu LL; Chen NN; Yu TT; Li TF; Li XY; Hu J
Sci Rep; 2024 May; 14(1):11704. PubMed ID: 38778121
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
Zhou HJ; Zhang JL; Li A; Wang Z; Lou XE
Cancer Chemother Pharmacol; 2010 May; 66(1):21-9. PubMed ID: 19756601
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
Li Y; Sun H; Bai C; Hu Y; Tang J; Zhang Y; Chen J; Zhong Z; He Y; Hu K; Yang J
Int Immunopharmacol; 2024 May; 133():112157. PubMed ID: 38678671
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells.
Liao K; Li J; Wang Z
Int J Clin Exp Pathol; 2014; 7(12):8684-91. PubMed ID: 25674233
[TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Lai XY; Shi YM; Zhou MM
Kaohsiung J Med Sci; 2023 Jul; 39(7):699-709. PubMed ID: 37057810
[TBL] [Abstract][Full Text] [Related]
6. Dihydroartemisinin Sensitizes Human Lung Adenocarcinoma A549 Cells to Arsenic Trioxide via Apoptosis.
Chen H; Gu S; Dai H; Li X; Zhang Z
Biol Trace Elem Res; 2017 Oct; 179(2):203-212. PubMed ID: 28261759
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS.
Han N; Li LG; Peng XC; Ma QL; Yang ZY; Wang XY; Li J; Li QR; Yu TT; Xu HZ; Xu X; Chen X; Wang MF; Li TF
Eur J Pharmacol; 2022 Mar; 919():174797. PubMed ID: 35122867
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy.
Han N; Yang ZY; Xie ZX; Xu HZ; Yu TT; Li QR; Li LG; Peng XC; Yang XX; Hu J; Xu X; Chen X; Wang MF; Li TF
Phytomedicine; 2023 Apr; 112():154682. PubMed ID: 36739636
[TBL] [Abstract][Full Text] [Related]
11. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
Shen R; Li J; Ye D; Wang Q; Fei J
Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):894-901. PubMed ID: 27590062
[TBL] [Abstract][Full Text] [Related]
12. Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.
Liu X; Wu J; Fan M; Shen C; Dai W; Bao Y; Liu JH; Yu BY
Cell Death Dis; 2018 Oct; 9(11):1048. PubMed ID: 30323180
[TBL] [Abstract][Full Text] [Related]
13. Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
Li Y; Xiao X; Wang H; Zhou Q; Jin Z; Zhang Y; Wang Y; Yue F; Zhou S; Yang J
Eur J Pharmacol; 2021 Oct; 909():174411. PubMed ID: 34390710
[TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells.
Mi YJ; Geng GJ; Zou ZZ; Gao J; Luo XY; Liu Y; Li N; Li CL; Chen YQ; Yu XY; Jiang J
PLoS One; 2015; 10(3):e0120426. PubMed ID: 25799586
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
16. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage.
Kuroda S; Tam J; Roth JA; Sokolov K; Ramesh R
Int J Nanomedicine; 2014; 9():3825-39. PubMed ID: 25143731
[TBL] [Abstract][Full Text] [Related]
17. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Nelson-Taylor SK; Le AT; Yoo M; Schubert L; Mishall KM; Doak A; Varella-Garcia M; Tan AC; Doebele RC
Mol Cancer Ther; 2017 Aug; 16(8):1623-1633. PubMed ID: 28500237
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro.
Mao H; Gu H; Qu X; Sun J; Song B; Gao W; Liu J; Shao Q
Int J Mol Med; 2013 Jan; 31(1):213-8. PubMed ID: 23138847
[TBL] [Abstract][Full Text] [Related]
19. Acidic Environment-Responsive Metal Organic Framework-Mediated Dihydroartemisinin Delivery for Triggering Production of Reactive Oxygen Species in Drug-Resistant Lung Cancer.
Yan X; Zhao X; Fan M; Zheng W; Zhu G; Li B; Wang L
Int J Nanomedicine; 2024; 19():3847-3859. PubMed ID: 38708182
[TBL] [Abstract][Full Text] [Related]
20. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.
Ahmed AU; Schmidt RL; Park CH; Reed NR; Hesse SE; Thomas CF; Molina JR; Deschamps C; Yang P; Aubry MC; Tang AH
J Natl Cancer Inst; 2008 Nov; 100(22):1606-29. PubMed ID: 19001609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
